We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ERS Genomics, Evolva Signs License Agreement

News   Oct 28, 2016

 
ERS Genomics, Evolva Signs License Agreement
 
 
 

RELATED ARTICLES

Alzheimer's Trafficking Defect Corrected in Rodents

News

UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.

READ MORE

CRISPR Could Restore Effectiveness of Lung Cancer Treatment

News

The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or "knocking out" a gene in cancer tumors that helps the tumors develop resistance to the drugs.

READ MORE

A Killer on Your Skin

News

Staphylococcus epidermidis is an ubiquitous colonizer of healthy human skin, but it is also a notorious source of serious nosocomial infections. Now, a new machine learning technique will help predict the risk of developing a serious, and possibly life-threatening S. epidermidis infection.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE